医学
嵌合抗原受体
CD8型
免疫系统
自然杀伤细胞
过继性细胞移植
抗原
淋巴细胞
免疫疗法
癌症研究
免疫学
肿瘤科
内科学
T细胞
细胞毒性T细胞
生物
生物化学
体外
作者
Michael C. Burger,Marie-Thérèse Forster,Annette Romanski,Florian Straßheimer,Jadranka Macas,Pia Susann Zeiner,Eike Steidl,Stefanie C. Herkt,Katharina Johanna Weber,Jonathan Schupp,Jennifer H. Lun,Maja Strecker,Karolin Wlotzka,Pinar Cakmak,Corinna Opitz,Rosemol George,Iris C. Mildenberger,Paulina Nowakowska,Congcong Zhang,Jasmin Röder
出处
期刊:Neuro-oncology
[Oxford University Press]
日期:2023-05-06
卷期号:25 (11): 2058-2071
被引量:161
标识
DOI:10.1093/neuonc/noad087
摘要
BACKGROUND: Glioblastoma (GB) is incurable at present without established treatment options for recurrent disease. In this phase I first-in-human clinical trial we investigated safety and feasibility of adoptive transfer of clonal chimeric antigen receptor (CAR)-NK cells (NK-92/5.28.z) targeting HER2, which is expressed at elevated levels by a subset of glioblastomas. METHODS: Nine patients with recurrent HER2-positive GB were treated with single doses of 1 × 107, 3 × 107, or 1 × 108 irradiated CAR-NK cells injected into the margins of the surgical cavity during relapse surgery. Imaging at baseline and follow-up, peripheral blood lymphocyte phenotyping and analyses of the immune architecture by multiplex immunohistochemistry and spatial digital profiling were performed. RESULTS: There were no dose-limiting toxicities, and none of the patients developed a cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome. Five patients showed stable disease after relapse surgery and CAR-NK injection that lasted 7 to 37 weeks. Four patients had progressive disease. Pseudoprogression was found at injection sites in 2 patients, suggestive of a treatment-induced immune response. For all patients, median progression-free survival was 7 weeks, and median overall survival was 31 weeks. Furthermore, the level of CD8+ T-cell infiltration in recurrent tumor tissue prior to CAR-NK cell injection positively correlated with time to progression. CONCLUSIONS: Intracranial injection of HER2-targeted CAR-NK cells is feasible and safe in patients with recurrent GB. 1 × 108 NK-92/5.28.z cells was determined as the maximum feasible dose for a subsequent expansion cohort with repetitive local injections of CAR-NK cells.
科研通智能强力驱动
Strongly Powered by AbleSci AI